Health ❯ Obesity

Treatment Options

Medications Pharmaceuticals Oral Medications Medication Weight Loss Drugs Clinical Trials Injectable Medications GLP-1 Agonists Drug Efficacy GLP-1 Receptor Agonists

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Early use patterns point to market expansion with many patients starting treatment with pills.

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

Germany Keeps GLP-1 Weight-Loss Drugs Off Statutory Coverage

Emcure Slashes Price of Novo’s Semaglutide Brand Poviztra by Up to 55% in India

Brazil Nears Semaglutide Patent Expiry as Anvisa Reviews 14 Filings and Novo Nordisk Counters

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

FDA Approves First Wegovy Pill for Chronic Weight Management

FDA Clears Wegovy Weight-Loss Pill, U.S. Launch Set for January

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

GLP-1 Drugs Are Changing What Households Buy, Study Finds

Brazil Cracks Down on Illicit Mounjaro Sales as Lilly Launches QR Verification Tool

Brazil’s Superior Court of Justice Rejects Semaglutide Patent Extension, Paving Way for 2026 Generics

Anvisa Approves Wegovy for MASH With Moderate-to-Advanced Fibrosis

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

France’s Drug Regulator Orders Halt to ‘GLP‑1’ Patch Sales on Seven Websites